Defined microbial communities and their soluble products protect mice from Clostridioides difficile infection.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
27 Jan 2024
27 Jan 2024
Historique:
received:
09
08
2023
accepted:
03
01
2024
medline:
28
1
2024
pubmed:
28
1
2024
entrez:
27
1
2024
Statut:
epublish
Résumé
Clostridioides difficile is the leading cause of antibiotic-associated infectious diarrhea. The development of C.difficile infection is tied to perturbations of the bacterial community in the gastrointestinal tract, called the gastrointestinal microbiota. Repairing the gastrointestinal microbiota by introducing lab-designed bacterial communities, or defined microbial communities, has recently shown promise as therapeutics against C.difficile infection, however, the mechanisms of action of defined microbial communities remain unclear. Using an antibiotic- C.difficile mouse model, we report the ability of an 18-member community and a refined 4-member community to protect mice from two ribotypes of C.difficile (CD027, CD078; p < 0.05). Furthermore, bacteria-free supernatant delivered orally to mice from the 4-member community proteolyzed C.difficile toxins in vitro and protected mice from C.difficile infection in vivo (p < 0.05). This study demonstrates that bacteria-free supernatant is sufficient to protect mice from C.difficile; and could be further explored as a therapeutic strategy against C.difficile infection.
Identifiants
pubmed: 38280981
doi: 10.1038/s42003-024-05778-6
pii: 10.1038/s42003-024-05778-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135Informations de copyright
© 2024. The Author(s).
Références
Round, J. L., O’Connell, R. M. & Mazmanian, S. K. Coordination of tolerogenic immune responses by the commensal microbiota. J. Autoimmun. 34, J220–J225 (2010).
pubmed: 19963349
doi: 10.1016/j.jaut.2009.11.007
Mazmanian, S. K., Liu, C. H., Tzianabos, A. O. & Kasper, D. L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122, 107–118 (2005).
pubmed: 16009137
doi: 10.1016/j.cell.2005.05.007
Kamada, N., Seo, S.-U., Chen, G. Y. & Nunez, G. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13, 321–335 (2013).
pubmed: 23618829
doi: 10.1038/nri3430
Pickard, J. M. & Nunez, G. Pathogen colonization resistance in the gut and its manipulation for improved health. Am. J. Pathol. 189, 1300–1310 (2019).
pubmed: 31100210
pmcid: 6617533
doi: 10.1016/j.ajpath.2019.03.003
Cleary, R. K. Clostridium difficile-associated diarrhea and colitis: clinical manifestations, diagnosis, and treatment. Dis. Colon Rectum 41, 1435–1449 (1998).
pubmed: 9823813
doi: 10.1007/BF02237064
Czepiel, J. et al. Clostridium difficile infection: review. Eur. J. Clin. Microbiol. Infect. Dis. 38, 1211–1221 (2019).
pubmed: 30945014
pmcid: 6570665
doi: 10.1007/s10096-019-03539-6
Balsells, E. et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J. Glob. Health 9, 010407 (2019).
pubmed: 30603078
doi: 10.7189/jogh.09.010407
Carlson, P. E. Jr. et al. The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates. Anaerobe 24, 109–116 (2013).
pubmed: 23608205
pmcid: 4038106
doi: 10.1016/j.anaerobe.2013.04.003
Fatima, R. & Aziz, M. The hypervirulent strain of Clostridium Difficile: NAP1/B1/027 - a brief overview. Cureus 11, e3977 (2019).
pubmed: 30967977
pmcid: 6440555
Loo, V. G. et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442–2449 (2005).
pubmed: 16322602
doi: 10.1056/NEJMoa051639
Sayedy, L., Kothari, D. & Richards, R. J. Toxic megacolon associated Clostridium difficile colitis. World J. Gastrointest. Endosc. 2, 293–297 (2010).
pubmed: 21160629
pmcid: 2999149
doi: 10.4253/wjge.v2.i8.293
Marsh, J. W. & Curry, S. R. Therapeutic approaches for Clostridium difficile infections. Curr. Protoc. Microbiol. 30, 1–9 (2013). 9A 3.
Wilcox, M. H. et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. J. Antimicrob. Chemother. 72, 2647–2656 (2017).
pubmed: 28633368
doi: 10.1093/jac/dkx174
Babakhani, F. et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68, 515–522 (2013).
pubmed: 23208832
doi: 10.1093/jac/dks450
Rohlke, F. & Stollman, N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap. Adv. Gastroenterol. 5, 403–420 (2012).
pubmed: 23152734
pmcid: 3491681
doi: 10.1177/1756283X12453637
Brandt, L. J. et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107, 10791087 (2012).
doi: 10.1038/ajg.2012.60
van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).
pubmed: 23323867
doi: 10.1056/NEJMoa1205037
Britton, R. A. & Young, V. B. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 20, 313–319 (2012).
pubmed: 22595318
pmcid: 3408078
doi: 10.1016/j.tim.2012.04.001
FDA. REBYOTA Highlights of Prescribing Information (2022).
Parvathy, S. N. et al. Enhanced donor screening for faecal microbial transplantation during COVID-19. Gut 70, 2219–2220 (2021).
pubmed: 33789964
doi: 10.1136/gutjnl-2021-324593
Hota, S. S. et al. Regional variability in fecal microbiota transplantation practices: a survey of the Southern Ontario Fecal Microbiota Transplantation Movement. CMAJ Open 6, E184–E190 (2018).
pubmed: 29674329
pmcid: 7869690
doi: 10.9778/cmajo.20170109
Hota, S. S. Challenges establishing a multi-purpose fecal microbiota transplantation stool donor program in Toronto, Canada. JAMMI 4, 218–226 (2019).
pubmed: 36339288
pmcid: 9612805
DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043–2050 (2019).
pubmed: 31665575
doi: 10.1056/NEJMoa1910437
Pierson, T. C. & Diamond, M. S. The emergence of Zika virus and its new clinical syndromes. Nature 560, 573–581 (2018).
pubmed: 30158602
doi: 10.1038/s41586-018-0446-y
Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D. & de Wit, E. A novel coronavirus emerging in china - key questions for impact assessment. N. Engl. J. Med. 382, 692–694 (2020).
pubmed: 31978293
doi: 10.1056/NEJMp2000929
Martz, S. L. et al. A human gut ecosystem protects against C. difficile disease by targeting TcdA. J. Gastroenterol. 52, 452–465 (2017).
pubmed: 27329502
doi: 10.1007/s00535-016-1232-y
Petrof, E. O. et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 1, 3 (2013).
pubmed: 24467987
pmcid: 3869191
doi: 10.1186/2049-2618-1-3
Yelin, I. et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat. Med. 25, 1728–1732 (2019).
pubmed: 31700189
pmcid: 6980696
doi: 10.1038/s41591-019-0626-9
Howerton, A., Patra, M. & Abel-Santos, E. Fate of ingested Clostridium difficile spores in mice. PloS one 8, e72620 (2013).
pubmed: 24023628
pmcid: 3758320
doi: 10.1371/journal.pone.0072620
Aldeen, W. E. et al. Comparison of the TOX A/B test to a cell culture cytotoxicity assay for the detection of Clostridium difficile in stools. Diagn. Microbiol. Infect. Dis. 36, 211–213 (2000).
pubmed: 10764962
doi: 10.1016/S0732-8893(00)00113-9
Dillon, S. T. et al. Involvement of Ras-related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B. Infect. Immun. 63, 1421–1426 (1995).
pubmed: 7890404
pmcid: 173169
doi: 10.1128/iai.63.4.1421-1426.1995
Huang, J. et al. Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis. Nat. Microbiol. 4, 269–279 (2019).
pubmed: 30510170
doi: 10.1038/s41564-018-0300-x
Just, I. et al. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375, 500–503 (1995).
pubmed: 7777059
doi: 10.1038/375500a0
Henkel, J. S., Baldwin, M. R. & Barbieri, J. T. Toxins from bacteria. EXS 100, 1–29 (2010).
pubmed: 20358680
pmcid: 3564551
Rudkin, J. K., McLoughlin, R. M., Preston, A. & Massey, R. C. Bacterial toxins: offensive, defensive, or something else altogether? PLoS Pathog. 13, e1006452 (2017).
pubmed: 28934339
pmcid: 5608399
doi: 10.1371/journal.ppat.1006452
Elliott, B., Dingle, K. E., Didelot, X., Crook, D. W. & Riley, T. V. The complexity and diversity of the Pathogenicity Locus in Clostridium difficile clade 5. Genome Biol. Evol. 6, 31593170 (2014).
doi: 10.1093/gbe/evu248
Wilcox, M. H. et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N. Engl. J. Med. 376, 305–317 (2017).
pubmed: 28121498
doi: 10.1056/NEJMoa1602615
Louie, T. J. et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 43, 411–420 (2006).
pubmed: 16838228
doi: 10.1086/506349
Darkoh, C., DuPont, H. L., Norris, S. J. & Kaplan, H. B. Toxin synthesis by Clostridium difficile is regulated through quorum signaling. mBio 6, e02569 (2015).
pubmed: 25714717
pmcid: 4453554
doi: 10.1128/mBio.02569-14
Kociolek, L. K. & Gerding, D. N. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat. Rev. Gastroenterol. Hepatol. 13, 150–160 (2016).
pubmed: 26860266
doi: 10.1038/nrgastro.2015.220
Darkoh, C., Deaton, M. & DuPont, H. L. Nonantimicrobial drug targets for Clostridium difficile infections. Future Microbiol. 12, 975–985 (2017).
pubmed: 28759258
pmcid: 5618939
doi: 10.2217/fmb-2017-0024
O’Grady, K., Knight, D. R. & Riley, T. V. Antimicrobial resistance in Clostridioides difficile. Eur. J. Clin. Microbiol. Infect. Dis. 40, 2459–2478 (2021).
pubmed: 34427801
doi: 10.1007/s10096-021-04311-5
Ranjbar, R. & Farahani, A. Antibiotic-resistance mechanisms and new horizons for treatment. Infect. Drug Resist. 12, 3137–3167 (2019).
pubmed: 31632102
pmcid: 6789722
doi: 10.2147/IDR.S219755
Castagliuolo, I., Riegler, M. F., Valenick, L., LaMont, J. T. & Pothoulakis, C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect. Immun. 67, 302–307 (1999).
pubmed: 9864230
pmcid: 96311
doi: 10.1128/IAI.67.1.302-307.1999
Culp, E. & Wright, G. D. Bacterial proteases, untapped antimicrobial drug targets. J. Antibiot. (Tokyo) 70, 366–377 (2017).
pubmed: 27899793
doi: 10.1038/ja.2016.138
Breidenstein, E. B. et al. The Lon protease is essential for full virulence in Pseudomonas aeruginosa. PLoS ONE 7, e49123 (2012).
pubmed: 23145092
pmcid: 3492299
doi: 10.1371/journal.pone.0049123
Langklotz, S., Baumann, U. & Narberhaus, F. Structure and function of the bacterial AAA protease FtsH. Biochim. Biophys. Acta 1823, 40–48 (2012).
pubmed: 21925212
doi: 10.1016/j.bbamcr.2011.08.015
Raju, R. M., Goldberg, A. L. & Rubin, E. J. Bacterial proteolytic complexes as therapeutic targets. Nat. Rev. Drug Discov. 11, 777–789 (2012).
pubmed: 23023677
doi: 10.1038/nrd3846
Sheth, P. M. et al. Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital. PLoS ONE 14, e0207138 (2019).
pubmed: 30742636
pmcid: 6370182
doi: 10.1371/journal.pone.0207138
Chen, X. et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135, 1984–1992 (2008).
pubmed: 18848941
doi: 10.1053/j.gastro.2008.09.002
Shelby, R. D. et al. Development of a standardized scoring system to assess a murine model of Clostridium difficile colitis. J. Invest. Surg. 33, 887–895 (2020).
pubmed: 30892111
doi: 10.1080/08941939.2019.1571129
Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 37, 852–857 (2019).
pubmed: 31341288
pmcid: 7015180
doi: 10.1038/s41587-019-0209-9
Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 13, 581–583 (2016).
pubmed: 27214047
pmcid: 4927377
doi: 10.1038/nmeth.3869
Pedregosa, F. et al. Scikit-learn: machine learning in python. J. Mach. Learn. Res. 12, 2825–2830 (2011).
McDonald, D. et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 6, 610–618 (2012).
pubmed: 22134646
doi: 10.1038/ismej.2011.139